Monoclonal antibodies such as Infliximab and Adalimumab inhibit atypical activation of NF-κB pathway by reducing TNF-α levels, which has the potential to relieve symptoms in critically ill patients with COVID-19 (116). Here, NFKB1 is linked to COVID-19.